Hepatitis B Vaccine Trials, Experience and Review
Demonstrating the relationship between Australia antigen and hepatitis B virus in the late 1960’s created a serologic means for detecting hepatitis B infection, disease, carriers, and recovery (1,2). This information provided an impetus for vaccine development even in the absence of a means to propagate the virus in the laboratory. Individuals chronically infected with hepatitis B could be identified and their infected plasma containing infectious hepatitis B virus (HBV) or Dane particles and excess hepatitis B surface antigen (HBsAg) obtained by plasmaphoresis (3). Additional markers (shown in Figure 1) of human hepatitis B infection and recovery were further identified as important serologic markers. These include hepatitis B surface antigen (HBsAg) and its antibody (anti-HBs), hepatitis B core antigen and its antibody (anti-HBc), and the hepatitis Beantigen and its antibody (anti-HBe). By use of these and other tests, it is possible to identify susceptibles from immunes and the probable state of infection of the carriers. Persons who have never had hepatitis B are free of all markers.
KeywordsProtective Efficacy Vaccine Trial Untoward Effect Seroconversion Rate Core Antigen
Unable to display preview. Download preview PDF.
- 3.Vyas, G. N., Cohen, S. N., and Schmid, R. (1978). Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention, Franklin Institute Press, Philadelphia.Google Scholar
- 5.Hilleman, M. R., McAlleer, W. J., and McLean, A. A. (1981). Human Hepatitis B Vaccine, Proc. Europ. Symp. on Hepatitis B, KPR Inform/Media, New York, pp. 120–139.Google Scholar
- 8.Szmuness, W., Alter, J. H., and Maynard, J. E. (1981). Viral Hepatitis, 1981 International Symposium, Franklin Institute Press, Philadelphia.Google Scholar
- 9.Morbidity and Mortality Weekly Report 31:317–322; 327–328, 1982.Google Scholar